<DOC>
	<DOCNO>NCT02288247</DOCNO>
	<brief_summary>The purpose study understand benefit continue treatment medicine call enzalutamide , start treatment docetaxel prednisolone ( standard chemotherapy prostate cancer ) , prostate cancer gotten worse treated enzalutamide alone .</brief_summary>
	<brief_title>A Study Assess Benefit Treatment Beyond Progression With Enzalutamide Men Who Are Starting Treatment With Docetaxel After Worsening Their Prostate Cancer When Taking Enzalutamide Alone</brief_title>
	<detailed_description>The study conduct consecutive period open label treatment enzalutamide follow randomized double-blind treatment continue enzalutamide placebo , combination docetaxel prednisolone . Open Label ( Period 1 ) At Week 13 , subject assess prostate-specific antigen ( PSA ) imaging . Subjects confirm PSA response evidence radiographic progression ineligible participation Period 2 typically safety follow ; however , Period 1 treatment may continue subject long investigator considers clinical benefit ( stop initiation new antineoplastic therapy ) . Subjects confirm PSA response continue Period 1 disease progression . Randomization ( Period 2 ) 274 subject confirm disease progression enzalutamide alone continue meet eligibility criterion may proceed randomization . Treatment allocation 1:1 ratio , stratify disease progression Period 1 follow treatment : - Enzalutamide docetaxel prednisolone - Placebo docetaxel prednisolone</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate without neuroendocrine differentiation small cell feature ; Ongoing androgen deprivation therapy ( ADT ) luteinizing hormonereleasing hormone ( LHRH ) agonist antagonist stable dose schedule within 4 week initiation investigational medicinal product ( IMP ) , bilateral orchiectomy ( i.e. , surgical medical castration ) ; Metastatic disease document least 2 bone lesion bone scan , soft tissue disease document computed tomography ( CT ) /magnetic resonance imaging ( MRI ) ; Progressive disease study entry define follow occur set castrate level testosterone : Prostate specific antigen ( PSA ) progression define minimum three rise PSA level interval ≥ 1 week determination . Asymptomatic minimally symptomatic prostate cancer ( Brief Pain Inventory Short Form ( BPISF ) question 3 score &lt; 4 ) ; Eastern Cooperative Oncology Group ( ECOG ) performance score 01 ; Estimated life expectancy ≥ 12 month ; Be suitable willing receive chemotherapy part trial ; Able swallow IMP comply study requirement ; Subject agree participate another interventional study treatment . Prior treatment follow agent treatment prostate cancer : Aminoglutethimide ; Ketoconazole ; Abiraterone ; Enzalutamide participation clinical trial enzalutamide ; 223Ra , 89Sr , 153Sm , 186Re/188Re ; Immunomodulatory therapy ; Cytotoxic chemotherapy ; Participation clinical trial investigational agent inhibits AR androgen synthesis unless treatment placebo ; Current prior treatment within 4 week prior initiation IMP follow agent treatment prostate cancer : Antiandrogens ; 5α reductase inhibitor ; Estrogens ; Anabolic steroid ; Drugs antiandrogenic property ; Progestational agent ; Subject receive investigational therapy within 28 day 5 halflives whichever longer , prior initiation IMP ; Use opiate analgesia pain prostate cancer within 4 week prior initiation IMP ; Radiation therapy bone lesion prostatic bed within 4 week prior initiation IMP ; Major surgery within 4 week prior initiation IMP ; History seizure condition may predispose seizure time past . History loss consciousness transient ischemic attack within 12 month prior Screening ; Known suspect brain metastasis active leptomeningeal disease ; History another malignancy within previous 5 year nonmelanoma skin cancer ; Clinically significant cardiovascular disease ; Gastrointestinal disorder affect absorption ; Medical contraindication use prednisolone docetaxel ; Allergies active ingredient excipients study drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Metastatic Castration Resistant Prostate Cancer</keyword>
	<keyword>Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer</keyword>
	<keyword>Chemotherapy- Naïve</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castration-resistant</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Xtandi</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Prednisolone</keyword>
</DOC>